Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone vs. Bupropion ER Augmentation in Treatment-Resistant Depression
NCT00179244Phase 3Completed
- Sponsor
- Vanderbilt University
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risperidone in major depressive disorder (MDD) (2 arms), sponsored by Vanderbilt University. Primary endpoint: Montgomery Asberg Depression Rating Scale. Started Jul 2004; status: completed.
02
Drugs
risperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00179244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179244.